Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy T2 Biosystems stock | 1.18

Own T2 Biosystems stock in just a few minutes.


Fact checked

T2 Biosystems, Inc is a diagnostics & research business based in the US. T2 Biosystems shares (TTOO) are listed on the NASDAQ and all prices are listed in US Dollars. T2 Biosystems employs 118 staff and has a trailing 12-month revenue of around USD$13.4 million.

How to buy shares in T2 Biosystems

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for T2 Biosystems. Find the stock by name or ticker symbol: TTOO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until T2 Biosystems reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.18, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of T2 Biosystems, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of T2 Biosystems. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted T2 Biosystems's share price?

Since the stock market crash in March caused by coronavirus, T2 Biosystems's share price has had significant positive movement.

Its last market close was USD$1.18, which is 23.73% up on its pre-crash value of USD$0.9 and 402.13% up on the lowest point reached during the March crash when the shares fell as low as USD$0.235.

If you had bought USD$1,000 worth of T2 Biosystems shares at the start of February 2020, those shares would have been worth USD$492.99 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,463.84.

T2 Biosystems share price

Use our graph to track the performance of TTOO stocks over time.

T2 Biosystems shares at a glance

Information last updated 2020-11-19.
Latest market close USD$1.18
52-week range USD$0.235 - USD$1.95
50-day moving average USD$1.3
200-day moving average USD$1.2993
Wall St. target price USD$3.22
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.284

Buy T2 Biosystems shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy T2 Biosystems stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

T2 Biosystems price performance over time

Historical closes compared with the close of $1.18 from 2020-11-16

1 week (2020-11-13) N/A
1 month (2020-10-20) N/A
3 months (2020-08-20) N/A
6 months (2020-05-20) N/A
1 year (2019-11-20) N/A
2 years (2018-11-20) N/A
3 years (2017-11-20) N/A
5 years (2015-11-20) N/A

T2 Biosystems financials

Revenue TTM USD$13.4 million
Gross profit TTM USD$-24,754,000
Return on assets TTM -49.43%
Return on equity TTM 0%
Profit margin 0%
Book value $0.119
Market capitalisation USD$167.9 million

TTM: trailing 12 months

Shorting T2 Biosystems shares

There are currently 11.1 million T2 Biosystems shares held short by investors – that's known as T2 Biosystems's "short interest". This figure is 16.9% down from 13.4 million last month.

There are a few different ways that this level of interest in shorting T2 Biosystems shares can be evaluated.

T2 Biosystems's "short interest ratio" (SIR)

T2 Biosystems's "short interest ratio" (SIR) is the quantity of T2 Biosystems shares currently shorted divided by the average quantity of T2 Biosystems shares traded daily (recently around 2.8 million). T2 Biosystems's SIR currently stands at 4.01. In other words for every 100,000 T2 Biosystems shares traded daily on the market, roughly 4010 shares are currently held short.

However T2 Biosystems's short interest can also be evaluated against the total number of T2 Biosystems shares, or, against the total number of tradable T2 Biosystems shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case T2 Biosystems's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 T2 Biosystems shares in existence, roughly 80 shares are currently held short) or 0.079% of the tradable shares (for every 100,000 tradable T2 Biosystems shares, roughly 79 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against T2 Biosystems.

Find out more about how you can short T2 Biosystems stock.

T2 Biosystems share dividends

We're not expecting T2 Biosystems to pay a dividend over the next 12 months.

T2 Biosystems share price volatility

Over the last 12 months, T2 Biosystems's shares have ranged in value from as little as $0.235 up to $1.95. A popular way to gauge a stock's volatility is its "beta".

TTOO.US volatility(beta: 0.92)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while T2 Biosystems's is 0.92. This would suggest that T2 Biosystems's shares are less volatile than average (for this exchange).

T2 Biosystems overview

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site